Medistim ASA (LTS:0OCD) 3-Month Share Buyback Ratio: 0.00% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0OCD Medistim ASA LTS:0OCD
97 GF Score
Price kr259.00
GF Value kr263.26
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Medistim ASA 3-Month Share Buyback Ratio?

Medistim ASA LTS:0OCD 97 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates LTS:0OCD with a GF Score™ of 97/100 and a GF Value™ of kr263.26 (Fairly Valued). The stock has 4 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Medistim ASA's current 3-Month Share Buyback Ratio was 0.00%.


Medistim ASA  (LTS:0OCD) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Medistim ASA 3-Month Share Buyback Ratio Related Terms


LTS:0OCD vs ABT, SYK, MDT: 3-Month Share Buyback Ratio Comparison

For the Medical Devices subindustry, Medistim ASA's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medistim ASA 3-Month Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Medistim ASA's 3-Month Share Buyback Ratio falls into.


LTS:0OCD
97GF Score
Medistim ASA LTS:0OCD
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA 3-Month Share Buyback Ratio Calculation

Medistim ASA's 3-Month Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2026 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Mar. 2026 )
=(18.283 - 18.283) / 18.283
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
Medistim ASA (LTS:0OCD) has a 3-Month Share Buyback Ratio of 0.00 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Medistim ASA and its competitors.
Is Medistim ASA's 3-Month Share Buyback Ratio too high?
Medistim ASA's current 3-Month Share Buyback Ratio is 0.00. Overall, Medistim ASA has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's 3-Month Share Buyback Ratio compare to ABT and SYK?
Medistim ASA's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Medistim ASA and its competitors. Medistim ASA's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (LTS:0OCD) is currently considered Fairly Valued. The stock's GF Value™ is kr263.26, compared to a current price of kr259.00 — trading 1.6% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Medistim ASA's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Medistim ASA (LTS:0OCD), the current 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (LTS:0OCD) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of kr259.00 is trading 1.6% below its estimated GF Value™ of kr263.26. GuruFocus considers Medistim ASA to be Fairly Valued.

Key valuation signals for LTS:0OCD:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: kr263.26 vs. price of kr259.00 (1.6% below fair value)
  • GF Score™: 97/100 with 4 warning signs

No single metric tells the full story. See the LTS:0OCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
97GF Score

Get the complete analysis for LTS:0OCD

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr259.00
Price
kr263.26
GF Value